After a successful and highly productive first grant period, the Oregon Clinical and Translational Research Institute (OCTRI) is well positioned to have greater impact in the next grant period. OCTRI's goals are:
Specific Aim 1. Generate sustained OHSU and KPCHR research growth and productivity across the spectrum of translational science.
Specific Aim 2. Translate new biomedical knowledge into widespread advances in human health and healthcare reform.
Specific Aim 3. Create a regional consortium for clinical and translational research.
Specific Aim 4. Expand the impact of the strong OCTRI educational curriculum, develop an institution-wide, coordinated career development process that builds on the strengths of existing programs, and extend it throughout the region and nationally.
Specific Aim 5. Enhance key infrastructure programs to support local and regional clinical and translational research. These plans will build on major progress during the first grant period to further expand clinical and translational research, career development and benefits to human health. OCTRI will utilize a series of innovative partnerships to leverage CTSA support, expand its extensive collaborations with communities, and take advantage of a regional consortium of academic institutions working together to enhance translation. As a member of the CTSA Consortium, OCTRI will contribute unique expertise and resources to the combined effort to solve biomedical problems. Oregon Health and Science University and its partner institution Kaiser Permanente Center for Health Research have committed strong leadership support and substantial institutional commitment to OCTRI's continued mission.

Public Health Relevance

OCTRI will have a major influence on clinical and translational research at OHSU and KPCHR, and will increase their contributions to biomedical discovery. As the only academic medical center in Oregon, OHSU has a unique opportunity to catalyze translational research growth on a regional scale. Via its participation in the CTSA Consortium, OCTRI will advance national research productivity.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Training Award (TL1)
Project #
8TL1TR000129-07
Application #
8277877
Study Section
Special Emphasis Panel (ZRR1-CR-1 (01))
Program Officer
Sufian, Meryl
Project Start
2006-09-30
Project End
2016-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
7
Fiscal Year
2012
Total Cost
$152,559
Indirect Cost
$11,301
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Coleman, Daniel J; Van Hook, Kathryn; King, Carly J et al. (2016) Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget 7:40690-40703
Campbell, J Peter; Kalpathy-Cramer, Jayashree; Erdogmus, Deniz et al. (2016) Plus Disease in Retinopathy of Prematurity: A Continuous Spectrum of Vascular Abnormality as a Basis of Diagnostic Variability. Ophthalmology 123:2338-2344
Kalpathy-Cramer, Jayashree; Campbell, J Peter; Erdogmus, Deniz et al. (2016) Plus Disease in Retinopathy of Prematurity: Improving Diagnosis by Ranking Disease Severity and Using Quantitative Image Analysis. Ophthalmology 123:2345-2351
Noyd, David H; Sharp, Tyler M (2015) Recent Advances in Dengue: Relevance to Puerto Rico. P R Health Sci J 34:65-70
Niu, Brenda; Lee, Vanessa R; Cheng, Yvonne W et al. (2014) What is the optimal gestational age for women with gestational diabetes type A1 to deliver? Am J Obstet Gynecol 211:418.e1-6
Jones, Casey M; Baker-Groberg, Sandra M; Cianchetti, Flor A et al. (2014) Measurement science in the circulatory system. Cell Mol Bioeng 7:1-14
Zelaya, Jaime E; Goenezen, Sevan; Dargon, Phong T et al. (2014) Improving the efficiency of abdominal aortic aneurysm wall stress computations. PLoS One 9:e101353
Concannon, Thomas W; Guise, Jeanne-Marie; Dolor, Rowena J et al. (2014) A national strategy to develop pragmatic clinical trials infrastructure. Clin Transl Sci 7:164-71